Registered outcomes12

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

1 to 12 of 12

List	Outcome	Time frame
Primary	Incidence of adverse events (AEs)	Up to 2 years
Primary	Incidence of serious adverse events (SAEs)	Up to 2 years
Primary	Incidence of adverse events of special interest (AESI)	Up to 2 years
Primary	Incidence of AEs leading to discontinuation	Up to 2 years
Primary	Number of Deaths	Up to 2 years
Primary	Establish recommended Phase 2 dose (RP2D)	Up to 2 years
Secondary	Overall response rate (ORR)	Up to 2 years
Secondary	Complete response rate (CRR)	Up to 2 years
Secondary	Very good partial response rate (VGPRR)	Up to 2 years
Secondary	Maximum observed concentration (Cmax) of arlocabtagene autoleucel	Up to 2 years
Secondary	Time of maximum observed concentration (tmax) of arlocabtagene autoleucel	Up to 2 years
Secondary	Area under the concentration-time curve from time 0 to 28 days [AUC (0-28D)] of arlocabtagene autoleucel	Up to 2 years

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT06121843/registered